Literature DB >> 11312022

Acceptable protective efficacy of influenza vaccination in young military conscripts under circumstances of incomplete antigenic and genetic match.

R Pyhälä1, M Haanpää, M Kleemola, R Tervahauta, R Visakorpi, L Kinnunen.   

Abstract

Commercial inactivated parenteral influenza vaccines reduced febrile (> or = 38 degrees C) respiratory illness by 53% (95% CL: 41-63%) during a 3 week outbreak in 1998 when A/Sydney/5/97(H3N2)-like influenza viruses were shown to be the predominant etiological agents and an older antigenic variant, A/Nanchang/933/95, served as the vaccine virus. The calculatory efficacy for preventing virologically diagnosed influenza infections was 57% (95% CL: 40-68%). The study population consisted of 1374 young male military conscripts. Vaccination coverage on a voluntary basis was 67%. Vaccination was ineffective in preventing febrile illness during a second epidemic wave lasting 2 weeks when mainly adenoviruses were shown to have been circulating in the garrison. Out of the 36 nasopharyngeal aspirates positive for influenza A by antigen detection, 18 A/Sydney/5/97-like strains (10 from non-vaccinated and eight from vaccinated subjects) and two A/Nanchang/933/95-like strains (both from non-vaccinated subjects) were isolated in MDCK cell cultures. Intraepidemic variation was detected among the A/Sydney/5/97-like field strains in their HA1 sequences and reactivity in HI tests, but no evidence was obtained that this variation would have been of significance to the virus in breaking through the vaccination-induced immunity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11312022     DOI: 10.1016/s0264-410x(01)00010-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

Review 1.  Influenza vaccines: from surveillance through production to protection.

Authors:  Pritish K Tosh; Robert M Jacobson; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2010-01-29       Impact factor: 7.616

Review 2.  Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients.

Authors:  Arnt-Ove Hovden; Rebecca Jane Cox; Lars Reinhardt Haaheim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

Review 3.  Prevention and control of influenza in persons with chronic obstructive pulmonary disease.

Authors:  Pedro Plans-Rubió
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

Review 4.  Vaccines for preventing influenza in healthy adults.

Authors:  Vittorio Demicheli; Tom Jefferson; Eliana Ferroni; Alessandro Rivetti; Carlo Di Pietrantonj
Journal:  Cochrane Database Syst Rev       Date:  2018-02-01

5.  Safety and immunogenicity of 3 seasonal trivalent influenza vaccines in the Chinese military.

Authors:  Dongqi Gao; Huisuo Yang; Bing Deng; Gang Yin; Wenjing Song; Haiyang Zhang; Yapin Li
Journal:  Hum Vaccin Immunother       Date:  2016-06-27       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.